Abstract 699P
Background
As COVID-19 will likely became an epidemic disease, vaccination planning will be crucial for LS-mLC receiving anti-cancer therapy (ACT) in order to prolong effective immunity
Methods
According to the timing of BD and Sars-Cov2 infection (Cov-I) during oncological history, LC pts were allocated in three cohorts: A) Cov-I before PV or third BD; B) uninfected who completed PV during ACT; C) uninfected LC who had completed PV before cancer diagnosis and will receive BD after stating of ACT. As control cohorts, we included other cancer patients (mOC pts) who had completed PV and were candidate to BD during myelosuppressive (cohort D) or not-myelosuppressive (cohort E) ACT. The primary endpoints were seroprevalence of IgG Anti-spike-RBD (anti-S IgG) at two pre-defined time-points (T1: +30-90 days after BD; T2: + 6 months +/- 4 weeks after BD). As exploratory endpoint, we compared median pre-vaccination value of four cytokines (IL-6, IL-2R, TNF-α, IL-10) with post-BD values in immunotherapy-treated pts (IT-pts)
Results
Between October 2021 and February 2022, 113 LS-mLC patients were assigned in cohort A (20 pts), in cohort B (61 pts) or in cohort C (32 pts); 55 LS-mOC patients were allocated in cohort D (25 pts) and in cohort E (30 pts). Throughout the Omicron variant spread, 40 pts (24%) experienced Cov-I before T2 evaluation. Anti-S IgG qualitative seropositivity rate was 100% at T1 and 98.8% at T2. After 6-months FU, hybrid immunization (Cov-I before or after BD), was associated with higher median anti-S IgG trier compared to vaccine alone-induced immunity (p = <0.0001). In uninfected pts, median anti-S IgG titre was significantly lower in IT-treated patients compared to non-IT treated patients (p = 0.02); no difference was found when comparing myelosuppressive or not ACT. Among 68 IT-pts, 5 pts (7.3%) showed significant increase (≥ 1.5 fold) of at least two cytokines in post-BD samples, without reporting ir-AE
Conclusions
Administration BDs of COVID-19 mRNA vaccine in LS-mLC pts resulted effective and safe. In IT-pts without recent Cov-I, additional BDs should be considered to prolong serological immunity
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario A Gemelli-IRCCS.
Funding
Grant Award: Vaccinazione Anti-COVID-19 Nei Pazienti Oncologici, Sponsor: AIOM (Associazione Italiana di Oncologia Medica)/FICOG (Federation of Italian Cooperative Oncology Groups).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17